Jill Slansky
Concepts (330)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 14 | 2021 | 161 | 2.640 |
Why?
| | Receptors, Antigen, T-Cell | 15 | 2023 | 676 | 2.430 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2024 | 929 | 2.280 |
Why?
| | Antigens, Neoplasm | 13 | 2023 | 271 | 1.970 |
Why?
| | T-Lymphocytes | 14 | 2023 | 2007 | 1.770 |
Why?
| | Neoplasms | 13 | 2023 | 2944 | 1.730 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2023 | 155 | 1.670 |
Why?
| | Vaccines, Subunit | 4 | 2013 | 53 | 1.090 |
Why?
| | Peptides | 8 | 2023 | 991 | 0.900 |
Why?
| | T-Lymphocytes, Cytotoxic | 7 | 2022 | 180 | 0.890 |
Why?
| | Granzymes | 2 | 2024 | 51 | 0.890 |
Why?
| | Epitopes, T-Lymphocyte | 6 | 2012 | 175 | 0.870 |
Why?
| | Mice, Inbred BALB C | 18 | 2021 | 1244 | 0.710 |
Why?
| | Leukemia | 1 | 2024 | 246 | 0.690 |
Why?
| | Immunotherapy | 8 | 2021 | 669 | 0.670 |
Why?
| | Lymphocyte Activation | 11 | 2019 | 1136 | 0.670 |
Why?
| | Tumor Escape | 3 | 2019 | 50 | 0.650 |
Why?
| | Tumor Microenvironment | 8 | 2026 | 745 | 0.630 |
Why?
| | Baculoviridae | 3 | 2009 | 44 | 0.610 |
Why?
| | Neoplasms, Experimental | 2 | 2021 | 163 | 0.610 |
Why?
| | Antigen Presentation | 6 | 2018 | 209 | 0.610 |
Why?
| | Immunogenetic Phenomena | 1 | 2019 | 8 | 0.580 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.580 |
Why?
| | Peptide Library | 4 | 2013 | 91 | 0.580 |
Why?
| | Epitopes | 2 | 2020 | 479 | 0.560 |
Why?
| | Insecta | 3 | 2009 | 73 | 0.550 |
Why?
| | Animals | 49 | 2026 | 38030 | 0.550 |
Why?
| | Histocompatibility Antigens Class I | 6 | 2019 | 207 | 0.540 |
Why?
| | Major Histocompatibility Complex | 4 | 2008 | 233 | 0.530 |
Why?
| | H-2 Antigens | 5 | 2008 | 111 | 0.530 |
Why?
| | Mice | 35 | 2026 | 18266 | 0.510 |
Why?
| | Alternative Splicing | 1 | 2019 | 249 | 0.490 |
Why?
| | Breast Neoplasms | 5 | 2026 | 2411 | 0.480 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1429 | 0.460 |
Why?
| | Autoimmunity | 2 | 2020 | 924 | 0.440 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 443 | 0.420 |
Why?
| | Vaccines | 2 | 2010 | 389 | 0.420 |
Why?
| | Immune Tolerance | 3 | 2025 | 384 | 0.420 |
Why?
| | Up-Regulation | 3 | 2019 | 840 | 0.420 |
Why?
| | Antigens | 3 | 2019 | 350 | 0.410 |
Why?
| | Colorectal Neoplasms | 5 | 2019 | 870 | 0.410 |
Why?
| | Cytotoxicity, Immunologic | 6 | 2024 | 224 | 0.400 |
Why?
| | Colonic Neoplasms | 3 | 2012 | 257 | 0.370 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2019 | 1148 | 0.370 |
Why?
| | Allergy and Immunology | 1 | 2013 | 42 | 0.370 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 54 | 0.350 |
Why?
| | B-Lymphocytes | 1 | 2017 | 884 | 0.350 |
Why?
| | Antigenic Variation | 1 | 2011 | 12 | 0.350 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 12 | 0.350 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 97 | 0.330 |
Why?
| | Cell Cycle Proteins | 6 | 1997 | 629 | 0.300 |
Why?
| | Carrier Proteins | 6 | 1997 | 728 | 0.300 |
Why?
| | B7-H1 Antigen | 2 | 2025 | 245 | 0.300 |
Why?
| | Histocompatibility Antigens | 2 | 2020 | 102 | 0.300 |
Why?
| | DNA-Binding Proteins | 9 | 2018 | 1467 | 0.290 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 330 | 0.270 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1194 | 0.270 |
Why?
| | Mice, Transgenic | 6 | 2023 | 2131 | 0.270 |
Why?
| | Tetrahydrofolate Dehydrogenase | 4 | 1997 | 22 | 0.260 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 466 | 0.260 |
Why?
| | Cross Reactions | 2 | 2020 | 129 | 0.240 |
Why?
| | Cell Line, Tumor | 11 | 2026 | 3538 | 0.240 |
Why?
| | Inflammation | 4 | 2020 | 2915 | 0.240 |
Why?
| | Vaccination | 3 | 2010 | 1444 | 0.230 |
Why?
| | Liver Neoplasms | 4 | 2020 | 774 | 0.230 |
Why?
| | Nuclear Envelope | 1 | 2026 | 47 | 0.230 |
Why?
| | Heme | 1 | 2026 | 90 | 0.230 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2026 | 62 | 0.230 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 219 | 0.230 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2674 | 0.220 |
Why?
| | Flow Cytometry | 6 | 2016 | 1160 | 0.210 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2003 | 365 | 0.210 |
Why?
| | Humans | 38 | 2026 | 145625 | 0.210 |
Why?
| | Semaphorins | 1 | 2025 | 37 | 0.210 |
Why?
| | Graft Rejection | 2 | 2007 | 504 | 0.210 |
Why?
| | Mammary Glands, Animal | 1 | 2025 | 124 | 0.210 |
Why?
| | Transfection | 2 | 2026 | 914 | 0.200 |
Why?
| | Antigens, CD | 3 | 2025 | 559 | 0.200 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4565 | 0.200 |
Why?
| | Listeria monocytogenes | 3 | 2011 | 103 | 0.190 |
Why?
| | Lymphocyte Count | 4 | 2017 | 166 | 0.190 |
Why?
| | Models, Biological | 1 | 2010 | 1758 | 0.190 |
Why?
| | Amino Acid Substitution | 2 | 2020 | 295 | 0.180 |
Why?
| | Transcription Factors | 6 | 1997 | 1728 | 0.180 |
Why?
| | DNA | 4 | 2026 | 1418 | 0.170 |
Why?
| | Female | 24 | 2026 | 79080 | 0.170 |
Why?
| | Base Sequence | 7 | 2016 | 2119 | 0.170 |
Why?
| | Histocompatibility Antigen H-2D | 4 | 2022 | 20 | 0.170 |
Why?
| | Dendritic Cells | 3 | 2014 | 507 | 0.160 |
Why?
| | Aging | 2 | 2011 | 1983 | 0.160 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 9 | 0.160 |
Why?
| | Heterografts | 1 | 2021 | 143 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 69 | 0.150 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1996 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2019 | 268 | 0.150 |
Why?
| | Chemokines, CXC | 1 | 2019 | 68 | 0.150 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2019 | 37 | 0.150 |
Why?
| | Nanotechnology | 1 | 2020 | 113 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 429 | 0.140 |
Why?
| | Gene Editing | 1 | 2020 | 89 | 0.140 |
Why?
| | Interleukin-12 | 1 | 2019 | 115 | 0.140 |
Why?
| | Oligopeptides | 1 | 2000 | 264 | 0.140 |
Why?
| | Calcineurin | 1 | 2019 | 105 | 0.140 |
Why?
| | Gene Transfer Techniques | 1 | 2020 | 184 | 0.140 |
Why?
| | CRISPR-Cas Systems | 1 | 2020 | 163 | 0.140 |
Why?
| | Mice, Knockout | 5 | 2021 | 3121 | 0.140 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 33 | 0.140 |
Why?
| | Autoantigens | 1 | 2021 | 426 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 339 | 0.140 |
Why?
| | Mutation | 5 | 2020 | 4082 | 0.130 |
Why?
| | Macrophages | 1 | 2026 | 1530 | 0.130 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 91 | 0.130 |
Why?
| | Genetic Therapy | 1 | 2020 | 303 | 0.130 |
Why?
| | Cell Line | 2 | 2016 | 2809 | 0.130 |
Why?
| | Promoter Regions, Genetic | 5 | 1997 | 1236 | 0.130 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 474 | 0.130 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 218 | 0.130 |
Why?
| | Immunodominant Epitopes | 2 | 2010 | 27 | 0.130 |
Why?
| | Genetic Engineering | 2 | 2009 | 87 | 0.130 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 161 | 0.130 |
Why?
| | Tryptophan | 1 | 2018 | 183 | 0.120 |
Why?
| | Transcriptional Activation | 2 | 2018 | 368 | 0.120 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2018 | 166 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 751 | 0.120 |
Why?
| | Spodoptera | 2 | 2021 | 39 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 200 | 0.120 |
Why?
| | Mononuclear Phagocyte System | 1 | 2016 | 10 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 538 | 0.120 |
Why?
| | Ligands | 4 | 2018 | 676 | 0.120 |
Why?
| | Emulsions | 1 | 2016 | 58 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2017 | 324 | 0.120 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 100 | 0.120 |
Why?
| | Gene Expression Regulation | 4 | 2022 | 2591 | 0.110 |
Why?
| | Lymph Nodes | 2 | 2016 | 511 | 0.110 |
Why?
| | Phagocytes | 1 | 2016 | 79 | 0.110 |
Why?
| | Cell Separation | 1 | 2016 | 300 | 0.110 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 345 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 4 | 2007 | 415 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 1993 | 266 | 0.110 |
Why?
| | Lung | 3 | 2017 | 4119 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 641 | 0.110 |
Why?
| | Interferon-gamma | 5 | 2011 | 780 | 0.100 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1030 | 0.100 |
Why?
| | Retinoblastoma-Binding Protein 1 | 6 | 1997 | 22 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 598 | 0.100 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 563 | 0.100 |
Why?
| | E2F Transcription Factors | 6 | 1997 | 65 | 0.100 |
Why?
| | Transcription Factor DP1 | 5 | 1997 | 21 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2010 | 1790 | 0.090 |
Why?
| | Colorado | 2 | 2013 | 4588 | 0.090 |
Why?
| | Molecular Sequence Data | 8 | 2006 | 2835 | 0.090 |
Why?
| | Prognosis | 2 | 2020 | 4331 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 845 | 0.090 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2012 | 411 | 0.090 |
Why?
| | Transcription, Genetic | 3 | 1997 | 1429 | 0.080 |
Why?
| | Hemangiosarcoma | 1 | 2010 | 27 | 0.080 |
Why?
| | Universities | 1 | 2013 | 450 | 0.080 |
Why?
| | Lymphoma, B-Cell | 1 | 2012 | 149 | 0.080 |
Why?
| | Carcinoma | 1 | 2011 | 225 | 0.080 |
Why?
| | Research | 1 | 2013 | 421 | 0.070 |
Why?
| | Down-Regulation | 1 | 2011 | 612 | 0.070 |
Why?
| | Genes, MHC Class I | 1 | 2009 | 37 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 285 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 6021 | 0.070 |
Why?
| | Cross-Priming | 1 | 2008 | 17 | 0.070 |
Why?
| | CD11c Antigen | 1 | 2008 | 40 | 0.070 |
Why?
| | E2F1 Transcription Factor | 4 | 1997 | 68 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2009 | 243 | 0.060 |
Why?
| | Protein Conformation | 2 | 2003 | 914 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 928 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 371 | 0.060 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2006 | 64 | 0.060 |
Why?
| | Biomarkers | 1 | 2017 | 4329 | 0.060 |
Why?
| | Heme Oxygenase-1 | 1 | 2026 | 76 | 0.060 |
Why?
| | Bilirubin | 1 | 2026 | 101 | 0.060 |
Why?
| | Melanoma, Experimental | 1 | 2006 | 106 | 0.060 |
Why?
| | RNA, Messenger | 2 | 1994 | 2783 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2021 | 700 | 0.060 |
Why?
| | DNA Primers | 1 | 2006 | 487 | 0.060 |
Why?
| | Drug Design | 1 | 2006 | 179 | 0.060 |
Why?
| | Plasmids | 1 | 2026 | 372 | 0.050 |
Why?
| | Amino Acid Sequence | 5 | 2018 | 2088 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8351 | 0.050 |
Why?
| | G1 Phase | 2 | 1996 | 64 | 0.050 |
Why?
| | S Phase | 2 | 1996 | 77 | 0.050 |
Why?
| | Male | 8 | 2020 | 73014 | 0.050 |
Why?
| | Antigens, Surface | 2 | 2001 | 155 | 0.050 |
Why?
| | Clone Cells | 2 | 2003 | 259 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2011 | 4112 | 0.050 |
Why?
| | Mice, SCID | 2 | 2021 | 360 | 0.050 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2003 | 26 | 0.050 |
Why?
| | 3T3 Cells | 4 | 2003 | 152 | 0.050 |
Why?
| | Genes, erbB-2 | 1 | 2003 | 32 | 0.050 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 61 | 0.050 |
Why?
| | Cell Survival | 1 | 2026 | 1102 | 0.050 |
Why?
| | Transplantation Chimera | 1 | 2002 | 57 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 66 | 0.040 |
Why?
| | Molecular Conformation | 1 | 2022 | 141 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2003 | 434 | 0.040 |
Why?
| | Transglutaminases | 1 | 2022 | 137 | 0.040 |
Why?
| | Sf9 Cells | 1 | 2021 | 11 | 0.040 |
Why?
| | Middle Aged | 3 | 2020 | 36359 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2002 | 326 | 0.040 |
Why?
| | B7-1 Antigen | 1 | 2001 | 55 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 79 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 82 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2001 | 162 | 0.040 |
Why?
| | Surface Plasmon Resonance | 1 | 2000 | 87 | 0.040 |
Why?
| | Aged | 2 | 2017 | 26251 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1361 | 0.040 |
Why?
| | Dogs | 2 | 2012 | 516 | 0.040 |
Why?
| | Alanine | 1 | 2000 | 171 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 598 | 0.040 |
Why?
| | Cyclophosphamide | 2 | 2011 | 275 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2006 | 805 | 0.040 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1998 | 4 | 0.030 |
Why?
| | Models, Molecular | 1 | 2003 | 1571 | 0.030 |
Why?
| | Gene Products, tax | 1 | 1998 | 15 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.030 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 1998 | 25 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 5 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1511 | 0.030 |
Why?
| | Kynurenine | 1 | 2018 | 114 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1269 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 665 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1998 | 186 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 109 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 377 | 0.030 |
Why?
| | HLA Antigens | 1 | 2018 | 241 | 0.030 |
Why?
| | Folic Acid Antagonists | 1 | 1996 | 8 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 1996 | 24 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1996 | 87 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 179 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1996 | 90 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2078 | 0.030 |
Why?
| | Gene Amplification | 1 | 1996 | 116 | 0.030 |
Why?
| | Cadaver | 1 | 2016 | 302 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1062 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 22 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 13 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 29 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 58 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 60 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 43 | 0.030 |
Why?
| | Cell Division | 2 | 1993 | 735 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1033 | 0.030 |
Why?
| | DNA Replication | 1 | 1996 | 248 | 0.020 |
Why?
| | Cell Cycle | 2 | 1994 | 595 | 0.020 |
Why?
| | Culture Media, Serum-Free | 1 | 1993 | 42 | 0.020 |
Why?
| | Nuclear Proteins | 2 | 2001 | 739 | 0.020 |
Why?
| | Imidazoles | 1 | 2014 | 244 | 0.020 |
Why?
| | Serum Response Factor | 1 | 1993 | 33 | 0.020 |
Why?
| | Cloning, Molecular | 3 | 2001 | 526 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3186 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 1996 | 347 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2003 | 158 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2218 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 495 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 75 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 76 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2857 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 2079 | 0.020 |
Why?
| | Dimerization | 2 | 2001 | 174 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 105 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2010 | 19 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5397 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1202 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 423 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 447 | 0.020 |
Why?
| | ras Proteins | 1 | 2010 | 148 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 414 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1293 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1372 | 0.020 |
Why?
| | Protein Binding | 2 | 2006 | 2239 | 0.020 |
Why?
| | DNA, Complementary | 2 | 2001 | 269 | 0.020 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 129 | 0.020 |
Why?
| | Binding Sites | 3 | 1997 | 1306 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2003 | 693 | 0.020 |
Why?
| | Injections, Intradermal | 1 | 2006 | 13 | 0.020 |
Why?
| | Enterotoxins | 1 | 2006 | 89 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 238 | 0.010 |
Why?
| | Hepatitis | 1 | 2006 | 43 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2006 | 447 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2007 | 481 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 39 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2003 | 39 | 0.010 |
Why?
| | Vaccines, DNA | 1 | 2003 | 32 | 0.010 |
Why?
| | Adult | 2 | 2017 | 40821 | 0.010 |
Why?
| | Peptide Mapping | 1 | 2003 | 61 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 137 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2002 | 49 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2003 | 197 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 2003 | 197 | 0.010 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2002 | 35 | 0.010 |
Why?
| | Drug Synergism | 1 | 2003 | 353 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 2002 | 185 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2003 | 384 | 0.010 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2001 | 10 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 2001 | 28 | 0.010 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2001 | 14 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2002 | 415 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2001 | 57 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 878 | 0.010 |
Why?
| | Gene Library | 1 | 2001 | 121 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 382 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2001 | 186 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2002 | 280 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1041 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2001 | 326 | 0.010 |
Why?
| | HTLV-I Infections | 1 | 1998 | 29 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 1998 | 36 | 0.010 |
Why?
| | Image Cytometry | 1 | 1998 | 13 | 0.010 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 1998 | 34 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2001 | 429 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 662 | 0.010 |
Why?
| | Immunity, Active | 1 | 1998 | 8 | 0.010 |
Why?
| | E2F5 Transcription Factor | 1 | 1997 | 2 | 0.010 |
Why?
| | E2F4 Transcription Factor | 1 | 1997 | 6 | 0.010 |
Why?
| | Immunologic Memory | 1 | 1998 | 369 | 0.010 |
Why?
| | HeLa Cells | 1 | 1997 | 635 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 1021 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5574 | 0.010 |
Why?
| | Models, Genetic | 1 | 1997 | 537 | 0.010 |
Why?
| | Genes | 1 | 1994 | 215 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1994 | 505 | 0.010 |
Why?
| | Molecular Weight | 1 | 1992 | 295 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1992 | 369 | 0.010 |
Why?
| | Signal Transduction | 1 | 2001 | 5234 | 0.000 |
Why?
|
|
Slansky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|